FUJIFILM Biotechnologies Publishes FY2025 Sustainability Review – Progressing on its Partners for the Planet Ambition

  • Published on:
  • Press Release
Home | FUJIFILM Biotechnologies Publishes FY2025 Sustainability Review – Progressing on its Partners for the Planet Ambition

HILLERØD, Denmark, October 6, 2026 — FUJIFILM Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today published its annual sustainability review for FY2025 (covering fiscal year ending March 31, 2026), detailing its progress towards its Partners for the Planet 2030 ambition.

 

“As an integral part of the biopharmaceutical supply chain, we play an important role in helping deliver life-changing medicines. In addition to helping the lives of people, we firmly believe in doing our part to reduce our impact on the environment,” said Peter Skals, Head of Global Sustainability at FUJIFILM Biotechnologies. “Our ongoing efforts and accomplishments toward our sustainability goals were recently recognized via an award from a major customer. We’re very proud of this accomplishment, and it shows how sustainability and our business activities go hand-in-hand, driving operational excellence and reinforcing our partner ambition.”

 

Key achievements of FUJIFILM Biotechnologies’ Sustainability Review FY2025:

  • Renewable Electricity Progress: FUJIFILM Biotechnologies expanded renewable electricity procurement through the execution of a power purchase agreement supporting operations in Hillerød, Denmark, and through Fujifilm’s virtual power purchase agreement covering its U.S. sites. These agreements contributed to increasing renewable electricity coverage from 11% in FY2024 to 27% in FY2025. These renewable electricity agreements form part of the company’s longer-term target to source or match 100% of its electricity consumption with renewable electricity by 2030.
  • UK Expansion: The new, 110,000 sq. ft manufacturing expansion at FUJIFILM Biotechnologies’ site in Billingham, UK (the largest single-use biomanufacturing facility in the UK) uses electrically powered manufacturing systems for regular operations and includes membrane-based cold water-for-injection (WFI) production.
  • Denmark Site Electrification Progress: For one expansion at its Hillerød, Denmark site, FUJIFILM Biotechnologies commissioned two 3.5 MW electric boilers instead of adding new natural-gas-fired boiler capacity.
  • Independent Sustainability Assessments: During the latest assessment cycle from 2025 – 2026, FUJIFILM Biotechnologies’ Hillerød site achieved an EcoVadis Gold rating, while sites in Billingham, UK, Research Triangle Park and Holly Springs, North Carolina maintained Silver ratings. EcoVadis is a widely used sustainability ratings provider, and evaluates organizations across environmental, labor and human rights, ethics, and sustainable procurement criteria, providing an external benchmark.

 

Partners for the Planet is FUJIFILM Biotechnologies’ sustainability strategy. It provides a framework for defined initiatives and targets across operations, procurement, customer collaboration and the work environment, while aligning directly with the Fujifilm Group’s broader Sustainable Value Plan 2030. FUJIFILM Biotechnologies’ targets include:

  • Reducing CO2e emissions by 50% by 2030 (against a 2019 baseline year) with the goal of reaching net-zero by 2040.
  • Achieving 100% of electricity consumption from renewable sources by 2030.
  • Cutting supply chain CO2e emissions by 50% by 2030 (against a 2023 baseline).

 

To read the full review and learn more about FUJIFILM Biotechnologies’ sustainability goals and achievements, visit https://fujifilmbiotechnologies.fujifilm.com/about/sustainability/.

 

About FUJIFILM Biotechnologies 

FUJIFILM Biotechnologies, made up of several legal subsidiaries of FUJIFILM Corporation, is a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines and advanced therapies. With over 30 years of experience, the Company specializes in developing and manufacturing biopharmaceuticals using microbial, mammalian, and host/virus systems. With over 5,000 employees, FUJIFILM Biotechnologies operates an integrated network with major facilities in the United States, the United Kingdom, and Denmark. Under its kojoX philosophy, the Company aims to harmonize processes, procedures, systems, data, facility designs and equipment across its global manufacturing network to increase speed, while ensuring consistency, quality, scalability, and supply chain resilience. FUJIFILM Biotechnologies offers comprehensive services, ranging from proprietary cell line development, to process and analytical development, and through to clinical and commercial manufacturing. For more information, go to: fujifilmbiotechnologies.fujifilm.com.

 

About FUJIFILM Holdings Corporation
FUJIFILM Corporation is a subsidiary of FUJIFILM Holdings Corporation. Founded in 1934, FUJIFILM Holdings Corporation, headquartered in Tokyo, Japan, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of Healthcare, Electronics, Business Innovation and Imaging with over 70,000 employees. Guided and united by its Group Purpose of “Giving our world more smiles,” the company addresses social challenges and creates a positive impact on society through products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, Fujifilm aspires to continue its evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (24.8 billion EUR at an exchange rate of 161 JPY/EUR). For more information visit: www.fujifilmholdings.com.

 

Media Contact: 

Christine Jackman      
FUJIFILM Biotechnologies    
christine.jackman@fujifilm.com  
+1-914-261-4959